Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $56.0 million.

  • Dianthus Therapeutics' Cash & Equivalents rose 6626.77% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 6626.77%. This contributed to the annual value of $22.8 million for FY2024, which is 8277.57% down from last year.
  • Dianthus Therapeutics' Cash & Equivalents amounted to $56.0 million in Q3 2025, which was up 6626.77% from $13.2 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Cash & Equivalents high stood at $329.7 million for Q1 2024, and its period low was $10.1 million during Q1 2025.
  • Its 4-year average for Cash & Equivalents is $87.4 million, with a median of $40.3 million in 2023.
  • In the last 5 years, Dianthus Therapeutics' Cash & Equivalents skyrocketed by 132048.94% in 2024 and then plummeted by 9693.2% in 2025.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Cash & Equivalents stood at $15.4 million in 2022, then surged by 761.21% to $132.3 million in 2023, then plummeted by 82.78% to $22.8 million in 2024, then soared by 145.63% to $56.0 million in 2025.
  • Its last three reported values are $56.0 million in Q3 2025, $13.2 million for Q2 2025, and $10.1 million during Q1 2025.